SEC Tracker
Get the app

8-KANIP

Ani Pharmaceuticals reports Q3 2026 results

The press release states quarterly net revenues of $290.8 million, an increase of 27.6% year-over-year.1

By SEC Tracker ·

Ani PharmaceuticalsCIK 1023024Form 8-KFiled Nov 5, 2026, 6:57 AM ET0001023024-26-000077Read the filing on SEC.gov →

The company also announced an offer to acquire Egetis Therapeutics, expanding its Rare Disease business.2

Cortrophin Gel net revenues were $138.7 million in the third quarter of 2026, up 36.1% from the same period in 2025.3 ILUVIEN net revenues were $22.3 million, an increase of 34.1% year-over-year.4 Generics net revenues rose to $104.5 million, a 10.7% increase from the third quarter of 2025.5

The company reported quarterly GAAP net income of $35.1 million and adjusted non-GAAP EBITDA of $83.3 million, up 39.8% year-over-year.6 Diluted GAAP income per share was $1.51, and adjusted non-GAAP diluted earnings per share was $2.70.7 The company narrowed its 2026 revenue guidance to $1,085 - $1,125 million.8

The company also announced an offer to acquire Egetis Therapeutics, expanding its Rare Disease business.9 The press release was included in the Form 8-K filing.10

Key facts

Company
Ani Pharmaceuticals (ANIP)
CIK
1023024
Form
8-K
Items
2.02, 7.01, 9.01
Filed
Nov 5, 2026, 6:57 AM ET
Accession
0001023024-26-000077

From the EDGAR filing index, not written by AI.

Ani Pharmaceuticals results from its filings

Revenue, net income and cash as tagged in XBRL in the company's 10-Q and 10-K filings, up to this filing. Drawn in code; no figure here is written by AI.

Ani Pharmaceuticals revenue and net income by quarterRevenueNet income$ millionsSource: XBRL in the company's 10-Q and 10-K filings, SEC EDGAR0100200300Revenue · Q1 FY25: 197.1197.1Net income · Q1 FY25: 15.715.7Revenue · Q2 FY25: 211.4211.4Net income · Q2 FY25: 8.58.5Revenue · Q3 FY25: 227.8227.8Net income · Q3 FY25: 26.626.6Revenue · Q1 FY26: 237.5237.5Net income · Q1 FY26: 29.529.5Revenue · Q2 FY26: 266.0266.0Net income · Q2 FY26: 24.724.7Revenue · Q3 FY26: 290.8290.8Net income · Q3 FY26: 35.135.1Q1 FY25Q2 FY25Q3 FY25Q1 FY26Q2 FY26Q3 FY26
Ani Pharmaceuticals cash at period end$ millionsSource: XBRL in the company's 10-Q and 10-K filings, SEC EDGAR0100200300400500420.8FY24Q1 FY25Q2 FY25Q3 FY25FY25Q1 FY26Q2 FY26Q3 FY26Cash · FY24: 144.9Cash · Q1 FY25: 149.8Cash · Q2 FY25: 217.8Cash · Q3 FY25: 262.6Cash · FY25: 285.6Cash · Q1 FY26: 311.2Cash · Q2 FY26: 360.2Cash · Q3 FY26: 420.8
The numbers
PeriodRevenueNet incomeCashFiling
FY24$614.4M−$18.5M$144.9M10-K
Q1 FY25$197.1M$15.7M$149.8M10-Q
Q2 FY25$211.4M$8.5M$217.8M10-Q
Q3 FY25$227.8M$26.6M$262.6M10-Q
FY25$883.4M$78.3M$285.6M10-K
Q1 FY26$237.5M$29.5M$311.2M10-Q
Q2 FY26$266.0M$24.7M$360.2M10-Q
Q3 FY26$290.8M$35.1M$420.8M10-Q

How often Ani Pharmaceuticals files

Filings per calendar quarter, counted in code from the company's EDGAR filing list. Each bar splits 8-K current reports from other forms; the last bar is the quarter of this filing, counted up to it.

Ani Pharmaceuticals filings per quarter8-KOther formsSource: EDGAR filing list, counted in code010203040508-K · Q1 25: 6Other forms · Q1 25: 328-K · Q2 25: 5Other forms · Q2 25: 208-K · Q3 25: 6Other forms · Q3 25: 418-K · Q4 25: 3Other forms · Q4 25: 128-K · Q1 26: 3Other forms · Q1 26: 458-K · Q2 26: 4Other forms · Q2 26: 238-K · Q3 26: 2Other forms · Q3 26: 228-K · Q4 26: 2Other forms · Q4 26: 6382547154827248Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26
Ani Pharmaceuticals filings per quarter
The numbers
QuarterFilings8-K
Q1 25386
Q2 25255
Q3 25476
Q4 25153
Q1 26483
Q2 26274
Q3 26242
Q4 2682

Timeline

The company's filings on EDGAR around this one, newest first. Ownership forms and routine prospectus filings are left out.

  1. Form 8-KThis filing
  2. Form 8-K
  3. Form 10-Q
  4. Form 8-K
  5. Form 10-Q
  6. Form 8-K

Get an email when Ani Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Written with AI from the Ani Pharmaceuticals Form 8-K and checked against it sentence by sentence: each of the 10 numbered sentences opens the passage it comes from. AI can make mistakes. Check the filing. Not investment advice. Not affiliated with the U.S. SEC. Source filing on SEC.gov.

Data on this page was fetched . The filing on SEC.gov is the record.